AKT1 and metabolic dysfunction-associated steatotic liver disease: Besides it functions as a lipoprotein receptor (54), it interferes with lipid metabolism by inhibiting the synthesis of FASN and modulating the Akt-mTOR and Wnt signaling, in this way protecting again NAFLD and experimental carcinogenesis (9).